Silverback Therapeutics
500 Fairview Ave N
Suite 600
Seattle
WA
98109
United States
Tel: (206) 456-2900
Website: https://silverbacktx.com/
51 articles about Silverback Therapeutics
-
ARS Pharmaceuticals Closes Merger with Silverback Therapeutics
11/8/2022
ARS Pharmaceuticals, Inc. announced the closing of its merger with Silverback Therapeutics, Inc.
-
Silverback Therapeutics, Inc. announces the FDA’s acceptance of ARS Pharmaceuticals’ NDA for neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (type I) including Anaphylaxis
10/21/2022
Silverback Therapeutics, Inc. announces the FDA’s acceptance of ARS Pharmaceuticals’ NDA for neffy ® (epinephrine nasal spray) for the Treatment of Allergic Reactions (type I) including Anaphylaxis.
-
Silverback Therapeutics and ARS Pharmaceuticals Announce Merger
7/21/2022
Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”) and ARS Pharmaceuticals, Inc. (“ARS”) today announced that the companies have entered into a definitive agreement under which ARS will merge with Silverback in an all-stock transaction
-
Silverback Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
5/17/2022
Silverback Therapeutics, Inc. announced that Silverback management will participate in the H.C. Wainwright 24th Global Investment Conference from May 23-25, 2022.
-
Silverback Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
5/12/2022
Silverback Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2022 and provided a business update.
-
Silverback is halting its clinical oncology programs and letting go of about 27% of its workforce as part of a restructuring initiative that would leave it with more cash reserves.
-
Job cuts in biotech tend to occur during the end of a quarter, and the end of this first quarter is no different. Continue reading for news of four biotech companies making workforce layoffs this week.
-
Silverback Therapeutics Updates Strategic Priorities and Reports Fourth Quarter and Full Year 2021 Financial Results
3/31/2022
Silverback Therapeutics, Inc., a biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases, provided an update on strategic priorities and reported financial results for the fourth quarter and full year ended December 31, 2021.
-
That’s the advice for emerging growth life sciences companies in 2022, according to attorney Frank Rahmani, partner in the global life science and capital markets practice group at Sidley Austin LLP.
-
Silverback Therapeutics to Present at the 42nd Annual Cowen Healthcare Conference
2/24/2022
Silverback Therapeutics, Inc. announced that members of the Silverback management team will participate in the 42nd Annual Cowen Healthcare Conference from March 7-9, 2022.
-
Silverback Therapeutics to Participate in the SVB Leerink 11th Annual Global Healthcare Conference
2/3/2022
Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), today announced that Silverback management will participate in the SVB Leerink 11th Annual Global Healthcare Conference.
-
Silverback Therapeutics to Participate in the H.C. Wainwright Bioconnect Conference
1/5/2022
Silverback Therapeutics, Inc. announced that Silverback management will participate in the H.C. Wainwright Bioconnect Conference from January 10-13, 2022.
-
Silverback Therapeutics Presents SBT6050-201 Trial in Progress Poster at Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting
11/12/2021
Silverback Therapeutics Presents SBT6050-201 Trial in Progress Poster at Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting
-
Silverback Therapeutics Presents Preclinical Data for SBT8230 at AASLD The Liver Meeting 2021
11/12/2021
Silverback Therapeutics, Inc. today announced the presentation of preclinical data for SBT8230 at the American Association for the Study of Liver Diseases
-
Silverback Therapeutics to Participate in the Stifel 2021 Virtual Healthcare Conference
11/11/2021
Silverback Therapeutics, Inc., a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, announced that the Company will participate in the Stifel 2021 Virtual Healthcare Conference from November 15-17, 2021.
-
Silverback Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update
11/10/2021
Silverback Therapeutics, Inc. today reported financial results for the third quarter ended September 30, 2021, and provided a business update.
-
Silverback Therapeutics to Participate in the H.C. Wainwright Hepatitis B Virus (HBV) Conference
10/5/2021
Silverback Therapeutics, Inc. today announced that the Company will participate in the H.C. Wainwright Hepatitis B Virus (HBV) Conference on Wednesday, October 13, 2021.
-
Silverback Therapeutics Presents Interim Clinical Results from the Ongoing Phase 1/1b Study of SBT6050 Alone or In Combination with Pembrolizumab in Patients with Advanced or Metastatic HER2-Expressing Solid Tumors
9/16/2021
Silverback Therapeutics, Inc. presented interim clinical results from a Phase 1/1b clinical study of SBT6050 as a monotherapy and in combination with pembrolizumab in patients with advanced or metastatic HER2-expressing or amplified solid tumors, at the 2021 European Society for Medical Oncology Congress.
-
Silverback Therapeutics to Present Data from its Phase 1/1b Clinical Trial of SBT6050 at the European Society for Medical Oncology (ESMO) 2021 Virtual Congress
9/13/2021
Silverback Therapeutics, Inc. today announced that interim data from the dose-escalation portion of its Phase 1/1b clinical trial evaluating SBT6050 will be presented at the upcoming European Society for Medical Oncology (ESMO) 2021 Congress from September 16-21, 2021.
-
Silverback Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
9/7/2021
Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, today announced that the Company will participate in the H.C. Wainwright 23rd Annual Global Investment Conference.